Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO7049665 in Healthy Volunteers
NCT03221179Phase 1Completed
- Sponsor
- Roche
- Start
- Jul 2017
- Primary completion
- Jul 2019
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in ulcerative colitis (UC) and autoimmune hepatitis (AIH) comparing RO7049665 with Placebo (2 arms). Primary endpoint: Percentage of Participants with Adverse Events at 8 weeks. Started Jul 2017; status: completed.
02
Drugs
melredableukin alfa
03
Conditions
ulcerative colitis (UC)autoimmune hepatitis (AIH)
Beyond the preview
Go deeper on NCT03221179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03221179.